淋巴瘤

预约门诊

淋巴瘤分期

如果确诊淋巴瘤，下一步是确定癌症的扩散范围（称为分期）。影像学检查、血液检测和活检可能用于确定淋巴瘤的分期。医护团队使用癌症分期来帮助制定治疗计划。

淋巴瘤的分期可能会因具体类型不同而略有差异。总体而言，淋巴瘤的分期从 1 期到 4 期不等：

  • 淋巴瘤 1 期。 淋巴瘤 1 期仅累及一个淋巴结区域或淋巴结外的一个部位。
  • 淋巴瘤 2 期。 淋巴瘤 2 期累及膈膜同侧的两个或多个淋巴结区域。
  • 淋巴瘤 3 期。 淋巴瘤 3 期累及膈膜两侧的淋巴结区域。
  • 淋巴瘤 4 期。 淋巴瘤 4 期累及淋巴结以外的区域。

淋巴瘤预后

癌症预后能告知您癌症可被治疗或治愈的可能性。您的预后可能取决于：

  • 您的年龄。
  • 整体健康状况。
  • 您所患淋巴瘤的类型。
  • 癌症分期。
  • 您的血液检测结果。

如果您想了解预后情况，请咨询医护团队。医护团队成员可以阐明在评估您的预后时会考虑哪些因素。

申请预约
诊断与治疗生存率
Jan. 13, 2026

Living with 淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

mjlandin
Does anyone else have MGUS?

1141 Replies Sat, Feb 14, 2026

amyboylan1
Is there anything to help stop or slow progression of MGUS?

172 Replies Tue, Feb 10, 2026

See more discussions
  1. Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed Aug. 6, 2025.
  2. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Aug. 6, 2025.
  3. Primary CNS lymphoma treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed Aug. 6, 2025.
  4. Mycosis fungoides (including Sezary Syndrome) treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq. Accessed Aug. 6, 2025.
  5. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Aug. 6, 2025.
  6. Cancer stat facts: Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed Aug. 6, 2025.
  7. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  8. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  9. Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  10. Larson RA, et al. Tumor lysis syndrome: Prevention and treatment. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  11. Elsevier Point of Care. Clinical Overview: Febrile neutropenia in adults. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  12. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  13. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  14. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Aug. 6, 2025.
  15. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Aug. 6, 2025.

相关

相关医疗程序

产品与服务

淋巴瘤

CON-20304579